Penwest Pharmaceuticals Co. (PPCO) news stock charts
Penwest Pharmaceuticals Co. (PPCO) Investment Summary:
We are a drug development company dedicated to bringing to the marketplace innovative products that help improve the lives of patients. Our goal is to identify, develop and commercialize products that address unmet medical needs, primarily for disorders of the nervous system. We are currently applying our drug development and drug delivery expertise to a pipeline of potential products that are in various stages of development, and that we intend to commercialize independently or through third party alliances. On June 22, 2006, the United States Food and Drug Administration, or FDA, approved Opana® ER. Opana ER, an extended release formulation of oxymorphone hydrochloride, is a product that we developed with Endo Pharmaceuticals Inc., or Endo, using our proprietary TIMERx® drug delivery technology. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f17%2f0000950135-08-001840.html#FIS_BUSINESS"www.penw.com
Founded in 1991
PENWEST PHARMACEUTICALS CO (PPCO:NASDAQ)
LAST $3.52 USD
CHANGE TODAY -0.02 -0.56%
VOLUME 104.3K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of PENWEST PHARMACEUTICALS CO (PPCO)
|
OPEN
$3.55
|
PREVIOUS CLOSE
$3.54
|
|
|
DAY HIGH
$3.61
|
DAY LOW
$3.43
|
|
|
52 WEEK HIGH
03/19/10 - $3.61
|
52 WEEK LOW
03/24/09 - $1.45
|
|
|
MARKET CAP
111.8M
|
AVERAGE VOLUME 10 D
151.2K
|
|
|
EPS TTM
$-0.04
|
SHARES OUTSTANDING
31.8M
|
|
|
PPCO Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for PENWEST PHARMACEUTICALS CO (PPCO)
Penwest Pharmaceuticals Co. expected to Report Q1 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on March 4, 2010).
03/4/2010
Penwest Pharmaceuticals Co. expected to Report Q1 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on March 4, 2010).
Penwest Pharmaceuticals Co. Reports Net Cash Flow Results for the Full Year Ended December 31, 2009
03/4/2010
Penwest Pharmaceuticals Co. reported net cash flow results for the full year ended December 31, 2009. For the full year 2009, the companys operating activities provided net cash of $73,000, compared with $26 million of net cash used in operating activities for the full year 2008.
Penwest Pharmaceuticals Co. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009; Provides Earnings Guidance for the Full Year 2010
03/4/2010
Penwest Pharmaceuticals Co. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company reported total revenues of $6,989,000, income from operations of $1,370,000 and net income of $1,217,000 or $0.04 per basic and diluted share against total revenues of $5,118,000, loss from operations of $1,975,000 and net loss of $2,232,000 or $0.07 per basic and diluted share for the same period last year. For the year, the company reported total revenues of $23,812,000, loss from operations of $686,000 and net loss of $1,500,000 or $0.05 per basic and diluted share against total revenues of $8,534,000, loss from operations of $25,997,000 and net loss of $26,734,000 or $0.89 per basic and diluted share for the same period last year. The company provided earnings guidance for the full year 2010. For the full year 2010, the company expects revenue to be in the range of $43 million to $45 million. The company expects to be profitable for the full year 2010.
Penwest Pharmaceuticals Co. financial resources
PPCO Competitors
| Company | Last | Change |
| Depomed Inc | $3.13 USD | -0.14 |
| Elite Pharmaceuticals Inc | $0.10 USD | +0.0005 |
| Flamel Technologies SA | $8.47 USD | +0.47 |
| Labopharm Inc | C$1.48 CAD | -0.01 |
| SCOLR Pharma Inc | $0.84 USD | +0.0201 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | PPCO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.7x |
|
| Price/Book | 8.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 4.0x |
|
|
PPCO |
||
|
PPCO transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Penwest Pharmaceuticals Co.
Penwest Reports Fourth Quarter and Year End 2009 Financial Results
2010-03-09 05:53:31
Quote: Read article
Penwest to Present at Cowen & Company 30th Annual Healthcare Conference
2010-03-05 05:44:07
Quote: NasdaqPPCONewsthth at 4:45 pm EST.About Penwest PharmaceuticalsPenwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, or a-tocopherolquinone, a coenzyme Q10 analog demonstrated to improve mitochondrial function in-vitro. Penwest is also applying its drug delivery technologies and drug formulation expertise to the formulation of our collaborato...Read article
Penwest Reports Fourth Quarter and Year End 2009 Financial Results
2010-03-05 05:44:06
Quote: Read article
Q4 2009 Penwest Pharmaceuticals Earnings Release - Time Not Supplied
2010-03-05 05:44:06
Quote: Read article
Penwest Pharmaceuticals Co. Q4 2009 Earnings Call Transcript
2010-03-05 05:44:05
Quote: Penwest Pharmaceuticals Co. (PPCO)
Q4 2009 Earnings Call
March 4, 2010 11:00 am ET
Executives
Jennifer Good – President and CEO
Frank Muscolo – Corporate Controller and Chief Accounting Officer
Analysts
Greg Gilbert [ph]
Arthur Friedman – Friedman Asset Management
Presentation
Operator
Welcome to Penwest fourth quarter and year-end earnings call.
The matters discussed herein contain forward-looking statements for purposes of the Safe Harbor provisions under the Private Secur...Read article
PENWEST PHARMACEUTICALS CO Files SEC form 8-K, Results of Operations and Financial Condition
2010-03-05 05:44:05
Quote: Item 2.02.Results of Operations and Financial Condition.
On March 4, 2010, Penwest Pharmaceuticals Co. announced its financial
results for the quarter and year ended December 31, 2009. The full text of the
press release issued in connection with the announcement is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
The information in this Form 8-K (including Exhibit 99.1) is being
furnished and shall not be deemed "filed" for purpose...Read article
Penwest to Present at Cowen & Company 30th Annual Healthcare Conference
2010-03-04 06:07:33
Quote: PPCONewsthth at 4:45 pm EST.About Penwest PharmaceuticalsPenwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, or a-tocopherolquinone, a coenzyme Q10 analog demonstrated to improve mitochondrial function in-vitro. Penwest is also applying its drug delivery technologies and drug formulation expertise to the formulation of our collaborators' pr...Read article
Penwest Pharmaceuticals Earnings Call scheduled for Thu, Mar 4
2010-03-04 06:07:32
Quote: Call DetailsPenwest Pharmaceuticals Earnings Conference Call (Q4 2009)Scheduled
to start Thu, Mar 4, 2010, 11:00 am EasternAfter
the event has finished, the audio will be availablefrom
this page until Sat, Mar 5, 2011About Penwest PharmaceuticalsPPCO)Penwest Pharmaceuticals Co. develops pharmaceutical products based on drug delivery technologies with focus on products that address disorders of the nervous system. Its proprietary drug delivery technologies include TIMERx, a controlled-release tec...Read article
Penwest Fourth Quarter and Year End 2009 Financial Results Conference Call
2010-02-26 02:00:59
Quote: Operational developments, financial results and financial guidance for 2010 will also be discussed on the call.The conference call will include remarks by Jennifer Good, President and Chief Executive Officer, and Frank Muscolo, Controller and Chief Accounting Officer.Domestic Telephone Number: 877-675-5246International Telephone Number: 816-650-7863The conference ID is "58987357"www.penwest.com.About Penwest PharmaceuticalsPenwest is a drug development company focused on identifying and developi...Read article
Penwest Enters Into Fourth Research and Development Agreement With Otsuka Pharmaceutical
2010-02-25 05:14:55
Quote: Penwest received a financial payment for successfully achieving this milestone.About Penwest PharmaceuticalsPenwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, or alpha tocopherol quinone, a coenzyme Q10 analog demonstrated to improve mitochondrial function in-vitro. Penwest is also applying its drug delivery technologies and drug formulati...Read article
Penwest Fourth Quarter and Year End 2009 Financial Results Conference Call
2010-02-24 08:47:36
Quote: Operational developments, financial results and financial guidance for 2010 will also be discussed on the call.The conference call will include remarks by Jennifer Good, President and Chief Executive Officer, and Frank Muscolo, Controller and Chief Accounting Officer.Domestic Telephone Number: 877-675-5246International Telephone Number: 816-650-7863The conference ID is "58987357"www.penwest.com.About Penwest PharmaceuticalsPenwest is a drug development company focused on identifying and developi...Read article
Penwest Third Quarter 2009 Financial Results Conference Call
2010-02-09 05:36:13
Quote: Good, President and Chief Executive Officer, and Frank Muscolo, Controller and Chief Accounting Officer.Domestic Telephone Number:888-277-5064International Telephone Number:816-650-7863The conference ID is:37239507
www.penwest.com.
About Penwest Pharmaceuticals
Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, or alpha tocopherol quinon...Read article
Penwest Formulation Demonstrates Proof-of-Principal in Phase I Trial in Development Program With Otsuka Pharmaceutical
2010-02-09 05:36:13
Quote: Read article
Penwest Enters Into Fourth Research and Development Agreement With Otsuka Pharmaceutical
2010-02-09 05:36:11
Quote: Good, Penwest's President and CEO, said, "We are very pleased to have signed another research and development agreement with Otsuka. Otsuka is an important customer for us, and our scientific team will continue to work closely with them to successfully formulate their compounds."Penwest announced its first agreement with Otsuka in September 2007, the second in November 2008 and a third in June 2009. The Company also announced in October 2009 that one of the formulations from the first agre...Read article
Penwest Announces Initiation of Phase IIa Clinical Trial of A0001 in Patients With Friedreich's Ataxia
2010-02-09 05:36:11
Quote: Read article
Penwest Formulation Demonstrates Proof-of-Principal in Phase I Trial in Development Program With Otsuka Pharmaceutical
2010-02-08 03:25:28
Quote: Read article
Would you like to leave a comment about Penwest Pharmaceuticals Co. PPCO
Find out what social network information about Penwest Pharmaceuticals Co. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Penwest Pharmaceuticals Co.'s Stock there is more great penny stock and market information at Realpennies